ASweetLife Team, Author at ASweetLife

Type 2 Diabetes Patients Prefer Injectable Victoza to Oral Januvia

New Patient Reported Outcomes (PRO) data presented by today at the European Association for the Study of Diabetes (EASD) congress in Stockholm challenge the widespread perception that patients prefer oral to injected glucose-lowering therapies. Results from the 26-week, open-label study show that patients taking injectable Victoza (liraglutide 1.8 mg) reported significantly higher overall treatment satisfaction after 26 weeks than...

New Investigational Drug Improved HbA1c in Adults with Type 2 Diabetes

Bristol-Myers Squibb Company and AstraZeneca announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in HbA1c in adult patients with type 2 diabetes compared to glimepiride alone...

Sanofi-aventis’ Once-Daily Type 2 Diabetes Drug Lixisenatide Shows Significant Improvement in Glucose Control

Sanofi-aventis announced the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden...

Blueberries Keep Getting Better

According to a new study published in the October issue of The Journal of Nutrition, daily consumption of whole blueberries increases insulin…

Actos Ongoing FDA Safety Review: Potential Increased Risk of Bladder Cancer

The FDA notified healthcare professionals and patients that the Agency is reviewing data from an ongoing, ten-year epidemiological study designed to evaluate whether Actos (pioglitazone) is associated with an increased risk of bladder cancer. Findings from studies in animals and humans suggest this is a potential safety risk that needs further study. At this time, FDA has not concluded that Actos increases the risk of bladder cancer...

New Blood Markers for Diabetes May Help Identify Patients at Risk

Scientists have found that blood levels of some ribonucleic acids (microRNAs) are different among people with type 2 diabetes and those who subsequently develop the disease compared to healthy controls, according to research reported in Circulation Research: Journal of the American Heart Association...

Fasting With Diabetes: Ask Your Doctor First

With Ramadan just behind us, and Yom Kippur just ahead, fast is the word. Fasting is challenging for anyone, and for diabetics it's especially important to fast safely. The approach to safe fasting depends on your treatment. If you use only insulin sensitizers, you should not experience any major issues when fasting. For type 2 diabetics taking secretagogues (including incretin-based), just not taking them during the period of the fast should be sufficient.

Roche Stops Diabetes Drug Trial

Swiss drugmaker Roche has stopped giving patients its experimental diabetes treatment taspoglutide in late stage clinical trials due to a high rate of adverse reactions, marking a major blow to drug once seen to have $2 billion a year potential. The decision was based on a higher-than-expected rate of discontinuations due to gastrointestinal (GI) intolerability...

Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET

Santarus, Inc., S2 Therapeutics, Inc. and VeroScience LLC announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize CYCLOSET(R) (bromocriptine mesylate) tablets in the U.S. CYCLOSET is a prescription drug...

Rosh Hashana and the Pomegranate

Rosh Hashana, the Jewish New Year, is just around the corner. Traditionally, Rosh Hashana meals include apples and honey which symbolize a sweet new year, and guarantee a fast rise in blood glucose levels. So what's a diabetic to do? One option is, of course, to have a tiny bite and call it quits....